Last updated: 11 March 2024 at 6:11pm EST

Paula Ragan Net Worth




The estimated Net Worth of Paula Ragan is at least $4.08 Million dollars as of 11 March 2024. Paula Ragan owns over 49,678 units of X4 Pharmaceuticals stock worth over $527,897 and over the last 5 years he sold XFOR stock worth over $1,057,302. In addition, he makes $2,497,790 as President, Chief Executive Officer, Corporate Secretary und Director at X4 Pharmaceuticals.

Paula Ragan XFOR stock SEC Form 4 insiders trading

Paula has made over 33 trades of the X4 Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 49,678 units of XFOR stock worth $43,717 on 11 March 2024.

The largest trade he's ever made was selling 239,437 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $181,972. On average, Paula trades about 13,072 units every 35 days since 2019. As of 11 March 2024 he still owns at least 765,068 units of X4 Pharmaceuticals stock.

You can see the complete history of Paula Ragan stock trades at the bottom of the page.





Paula Ragan biography

Dr. Paula Ragan Ph.D. serves as President, Chief Executive Officer, Corporate Secretary, Director of the Company. Dr. Ragan has been the President, Chief Executive Officer and a member of the board of directors of X4 since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. From August 2012 to September 2014, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the company’s business development activities. Prior to that, from January 2007 to August 2012, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed post-doctoral studies at Harvard Medical School. Ragan’s perspective and experience as our President and Chief Executive Officer, which provides the board with historic knowledge, operational expertise and continuity, provides her with the qualifications and skills to serve on our board of directors.

What is the salary of Paula Ragan?

As the President, Chief Executive Officer, Corporate Secretary und Director of X4 Pharmaceuticals, the total compensation of Paula Ragan at X4 Pharmaceuticals is $2,497,790. There are no executives at X4 Pharmaceuticals getting paid more.



How old is Paula Ragan?

Paula Ragan is 50, he's been the President, Chief Executive Officer, Corporate Secretary und Director of X4 Pharmaceuticals since 2019. There are 9 older and 4 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.

What's Paula Ragan's mailing address?

Paula's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.

Insiders trading at X4 Pharmaceuticals

Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa und Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.



What does X4 Pharmaceuticals do?

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.



What does X4 Pharmaceuticals's logo look like?

X4 Pharmaceuticals, Inc. logo

Complete history of Paula Ragan stock trades at X4 Pharmaceuticals

Datum
#
Unternehmen
Insider
Trans.
Transaktion
Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
11 Mar 2024 Paula Ragan
Präsident und CEO
Verkauf 49,678 $0.88 $43,717
11 Mar 2024
765,068
12 Feb 2024 Paula Ragan
Präsident und CEO
Verkauf 21,695 $1.01 $21,912
12 Feb 2024
814,746
1 Nov 2023 Paula Ragan
Präsident und CEO
Verkauf 239,437 $0.76 $181,972
1 Nov 2023
836,441
23 Jun 2023 Paula Ragan
Präsident und CEO
Verkauf 6,724 $1.92 $12,910
23 Jun 2023
543,797
15 Jun 2023 Paula Ragan
Präsident und CEO
Verkauf 6,724 $2.23 $14,995
15 Jun 2023
550,521
31 May 2023 Paula Ragan
Präsident und CEO
Verkauf 6,292 $1.95 $12,269
31 May 2023
557,245
10 Mar 2023 Paula Ragan
Präsident und CEO
Verkauf 49,678 $0.84 $41,730
10 Mar 2023
563,537
13 Feb 2023 Paula Ragan
Präsident und CEO
Verkauf 21,695 $0.93 $20,176
13 Feb 2023
613,215
17 Aug 2022 Paula Ragan
Präsident und CEO
Verkauf 13,448 $1.16 $15,600
17 Aug 2022
634,910
24 Jun 2022 Paula Ragan
Präsident und CEO
Verkauf 6,724 $1.07 $7,195
24 Jun 2022
648,358
16 Jun 2022 Paula Ragan
Präsident und CEO
Verkauf 6,724 $1.07 $7,195
16 Jun 2022
655,082
3 Jun 2022 Paula Ragan
Präsident und CEO
Verkauf 6,292 $1.21 $7,613
3 Jun 2022
661,806
11 Feb 2022 Paula Ragan
Präsident und CEO
Verkauf 21,695 $1.56 $33,844
11 Feb 2022
447,309
17 Aug 2021 Paula Ragan
Präsident und CEO
Verkauf 13,448 $5.10 $68,585
17 Aug 2021
469,004
15 Jul 2021 Paula Ragan
Präsident und CEO
Verkauf 13,448 $5.78 $77,729
15 Jul 2021
482,452
2 Jun 2021 Paula Ragan
Präsident und CEO
Verkauf 2,400 $9.50 $22,800
2 Jun 2021
406,248
1 Jun 2021 Paula Ragan
Präsident und CEO
Verkauf 4,104 $9.41 $38,619
1 Jun 2021
408,648
3 May 2021 Paula Ragan
Präsident und CEO
Verkauf 2,400 $8.33 $19,992
3 May 2021
412,752
5 Apr 2021 Paula Ragan
Präsident und CEO
Verkauf 2,400 $9.17 $22,008
5 Apr 2021
415,152
2 Mar 2021 Paula Ragan
Präsident und CEO
Verkauf 2,400 $9.74 $23,376
2 Mar 2021
272,923
2 Feb 2021 Paula Ragan
Präsident und CEO
Verkauf 2,400 $7.88 $18,912
2 Feb 2021
275,323
5 Jan 2021 Paula Ragan
Präsident und CEO
Verkauf 2,400 $7.00 $16,800
5 Jan 2021
277,723
23 Dec 2020 Paula Ragan
Präsident und CEO
Verkauf 4,800 $7.00 $33,600
23 Dec 2020
280,123
5 Oct 2020 Paula Ragan
Präsident und CEO
Verkauf 1,797 $7.00 $12,579
5 Oct 2020
284,923
2 Oct 2020 Paula Ragan
Präsident und CEO
Verkauf 603 $7.00 $4,221
2 Oct 2020
286,720
9 Sep 2020 Paula Ragan
Präsident und CEO
Verkauf 8,840 $8.04 $71,074
9 Sep 2020
287,323
2 Sep 2020 Paula Ragan
Präsident und CEO
Verkauf 2,400 $7.99 $19,176
2 Sep 2020
296,163
3 Aug 2020 Paula Ragan
Präsident und CEO
Verkauf 2,400 $7.45 $17,880
3 Aug 2020
208,912
2 Jul 2020 Paula Ragan
Präsident und CEO
Verkauf 2,400 $9.05 $21,720
2 Jul 2020
211,312
1 Jun 2020 Paula Ragan
Präsident und CEO
Verkauf 16,382 $8.78 $143,834
1 Jun 2020
213,712
4 May 2020 Paula Ragan
Präsident und CEO
Verkauf 2,400 $8.92 $21,408
4 May 2020
230,094
2 Apr 2020 Paula Ragan
Präsident und CEO
Verkauf 2,400 $8.40 $20,160
2 Apr 2020
232,494
2 Mar 2020 Paula Ragan
Präsident und CEO
Verkauf 2,400 $10.64 $25,536
2 Mar 2020
234,894


X4 Pharmaceuticals executives and stock owners

X4 Pharmaceuticals executives and other stock owners filed with the SEC include: